Patents by Inventor David S. Thomson

David S. Thomson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Succinate derivative compounds useful as cysteine protease inhibitors
    Patent number: 6649642
    Abstract: Disclosed are novel succinate derivative compounds of the formula(I)/(Ia): wherein R1, R2, R3, R4, R5, R6, R7, X and A are defined herein. The compounds are useful as inhibitors of cysteine proteases. Also disclosed are methods of using and methods of making such compounds.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: November 18, 2003
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene Richard Hickey, Weimin Liu, David S. Thomson
  • Compounds useful as reversible inhibitors of cathepsin S
    Publication number: 20030158406
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I), (Ia) and (II), (IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: February 13, 2003
    Publication date: August 21, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Compounds useful as reversible inhibitors of cathepsin S
    Patent number: 6608057
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases.
    Type: Grant
    Filed: October 24, 2001
    Date of Patent: August 19, 2003
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Novel nitriles useful as reversible inhibitors of cysteine proteases
    Publication number: 20030119827
    Abstract: Disclosed are novel nitrile compounds of formula (I) further defined herein, which compounds are useful as reversible inhibitors of cysteine proteases such as cathepsin K, S, F, L and B. These compounds are useful for treating diseases and pathological conditions exacerbated by these proteases such as, but not limited to, osteoporosis, rheumatoid arthritis, multiple sclerosis, asthma and other autoimmune diseases, Alzheimer's disease, atherosclerosis. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: June 4, 2002
    Publication date: June 26, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Eugene R. Hickey, Younes Bekkali, Usha R. Patel, Denice Mary Spero, David S. Thomson, Erick Richard Roush Young
  • NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS
    Publication number: 20030087939
    Abstract: Disclosed are novel succinate derivative compounds of the formula (I)/(Ia): 1
    Type: Application
    Filed: October 23, 2002
    Publication date: May 8, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene Richard Hickey, Weimin Liu, David S.. Thomson
  • Compounds useful as reversible inhibitors of cysteine proteases
    Patent number: 6525052
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: February 25, 2003
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Methods and labeled molecules for determining ligand binding to steroid receptors
    Publication number: 20030017503
    Abstract: The invention relates to fluorescence polarization (FP) methods for detecting and evaluating ligand binding to steroid receptors which are associated with heat shock proteins (hsps). The invention also relates to novel labeled molecules, in particular, fluorescence probes, which are useful in the methods of the invention.
    Type: Application
    Filed: May 20, 2002
    Publication date: January 23, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Susan E. Goldrick, Richard M. Nelson, James J. Crute, Ruby C. Wasti, Gerald H. Nabozny, John R. Proudfoot, David S. Thomson
  • Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side effects
    Publication number: 20020151588
    Abstract: The invention relates to the use of glucocorticoid receptor ligands selectively antagonizing the transactivation activity of the glucocorticoid receptor (GR) without affecting the transrepression activity. Compounds having this profile can be used as co-medication with conventional glucocorticoids in the treatment of inflammation and immune diseases. An advantage of this combination therapy is that metabolic side-effects of glucocorticoids are antagonized and only the anti-inflammatory or anti-immune activity of the glucocorticoids is maintained. In such a combination therapy, higher doses of the glucocorticoid can be used leading to better therapeutic efficacy.
    Type: Application
    Filed: December 20, 2001
    Publication date: October 17, 2002
    Inventors: David S. Thomson, Hans Michael Jennewein, Michel Pairet, Frank Kalkbrenner, Stefan Kreideweiss
  • Novel compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20020137932
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: March 14, 2001
    Publication date: September 26, 2002
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R.R. Young
  • Compound useful as reversible inhibitors of cysteine proteases
    Patent number: 6420364
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: July 16, 2002
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Michel Jose Emmanuel, Leah L. Frye, Eugene R. Hickey, Weimin Liu, Tina Marie Morwick, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Compounds useful as reversible inhibitors of cathepsin S
    Publication number: 20020091259
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: February 24, 2002
    Publication date: July 11, 2002
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
    Patent number: 6395897
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: May 28, 2002
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Leah L. Frye, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20020058809
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: November 2, 2001
    Publication date: May 16, 2002
    Inventors: Michel Jose Emmanuel, Eugene R. Hickey, Weimin Liu, Denice Mary Spero, Sanxing Sun, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Novel succinate derivative compounds useful as cysteine protease inhibitors
    Publication number: 20010041700
    Abstract: Disclosed are novel succinate derivative compounds of the formula (I)/(Ia): 1
    Type: Application
    Filed: May 22, 2001
    Publication date: November 15, 2001
    Inventors: Younes Bekkali, Rajashehar Betageri, Michel Jose Emmanuel, Eugene Richard Hickey, Weimin Liu, Usha R. Patel, Denice Mary Spero, David S. Thomson, Yancey David Ward, Erick Richard Roush Young
  • Succinate derivative compounds useful as cysteine protease inhibitors
    Patent number: 6313117
    Abstract: Disclosed are novel succinate derivative compounds of the formula(I)/(Ia): wherein R1, R2, R3, R4, R5, R6, R7, X and A are defined herein. The compounds are useful as inhibitors of cysteine proteases. Also disclosed are methods of using and methods of making such compounds.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: November 6, 2001
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Rajashehar Betageri, Michel Jose Emmanuel, Eugene Richard Hickey, Weimin Liu, Usha R. Patel, Denice Mary Spero, David S. Thomson, Yancey David Ward, Erick Richard Roush Young, Sanxing Sun
  • Immunomodulatory, anti-inflammatory, and anti-proliferative compounds: 5,6-dideoxy, 5-amino derivatives of idose and 6-deoxy, 6-amino derivatives of glucose
    Patent number: 6060453
    Abstract: Compounds of this invention are 5,6-dideoxy, 5-amino derivatives of idose and 6-deoxy, 6-amino derivatives of glucose which exhibit immunomodulatory, anti-inflammatory, and anti-proliferative activity. Methods of preparation, pharmaceutical compositions containing the compounds and methods of treating inflammatory and/or autoimmune disorders employing the compounds are disclosed.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: May 9, 2000
    Assignee: Greenwich Pharmaceuticals Incorporated
    Inventors: David S. Thomson, Mary A. Korpusik, Thomas P. Lawler, III
  • Anti-proliferative and anti-inflammatory compounds: derivatives of pentose monosaccharides
    Patent number: 5432163
    Abstract: Compounds of this invention are derivatives of pentose monosaccharides which exhibit anti-proliferative and anti-inflammatory activity as well as intermediates for the synthesis of these compounds. Methods of preparation, pharmaceutical compositions containing the compounds and methods of treating inflammatory and/or autoimmune disorders employing the compounds are disclosed.
    Type: Grant
    Filed: November 13, 1992
    Date of Patent: July 11, 1995
    Assignee: Greenwich Pharmaceuticals Incorporated
    Inventors: M. Nayeem Akhtar, David S. Thomson, Sudershak K. Arora
  • Anti-proliferative and anti-inflammatory compounds: 5- or 6-deoxy hexose monosaccharides having a saturated nitrogen-containing heterocycle at the 5- or 6-position bound through the nitrogen atom
    Patent number: 5360792
    Abstract: The compounds of this invention are 5- or 6-deoxy hexose monosaccharides having a saturated nitrogen-containing heterocycle at the 5- or 6-position bound through the nitrogen atom. The saturated nitrogen-containing heterocycle substituent is shown by the following formula: ##STR1## where X is CH.sub.2, NH or O; and n ranges from 3-6. These hexose monosaccharides may also be ethereally substituted at least one other position. The compounds exhibit anti-proliferative and anti-inflammatory activity. Methods of preparation, pharmaceutical compositions containing the compounds and methods of treating inflammatory and/or autoimmune disorders employing the compounds are disclosed.
    Type: Grant
    Filed: June 29, 1992
    Date of Patent: November 1, 1994
    Assignee: Greenwich Pharmaceuticals Incorporated
    Inventors: Sudershan K. Arora, David S. Thomson, M. Nayeem Akhtar
  • Pharmaceutical compositions
    Patent number: 4764361
    Abstract: The invention includes novel pharmaceutical compositions for topical use in the therapy or prophylaxis of inflammatory skin diseases, a method of treating one or more such diseases, a novel, optically active N-substituted-isobutyramide as an active ingredient and a process for the manufacture of said novel active ingredient.
    Type: Grant
    Filed: March 11, 1987
    Date of Patent: August 16, 1988
    Assignee: Imperial Chemical Industries PLC
    Inventors: Andrew J. T. Bilski, Ralph Howe, Balbir Rao, David S. Thomson
  • Halogenophenyl glyceride esters for use in the prophylaxis and/or therapy of acne vulgaris
    Patent number: 4587262
    Abstract: The invention concerns novel glyceride esters of anti-bacterial halogenated phenols having the formula I in which Ra and Rb are independently (3-20C)alkyl or (3-20C)alkenyl; Rc and Rd are independently chloro or bromo; Re is hydrogen, chloro or bromo; and A is (1-6C)alkylene optionally bearing one or two (1-4C)alkyl substituents.The esters are of use in the prophylaxis and/or therapy of acne vulgaris. Pharmaceutical compositions for topical administration and processes for the manufacture of the esters are also provided.
    Type: Grant
    Filed: June 6, 1983
    Date of Patent: May 6, 1986
    Assignee: Imperial Chemical Industries PLC
    Inventors: Jean C. Arnould, John R. Evans, Geraint Jones, David S. Thomson